Changes in protein glycosylation are associated with most diseases including congenital disorders of glycosylation, autoimmunity and cancer. Technology is an available which enables glycosylation changes to be associated with pathways and disease phenotypes. Determining which glycoproteins and pathways are affected in individual patients and predicting their responses to drug therapies is becoming an increasingly important aspect of personalised medicine. This talk will focus on the technologies needed to access big data sets for individuals and the bioInformatics programs which underpin data interpretation.